Search

Your search keyword '"Pinder-Schenck M"' showing total 16 results

Search Constraints

Start Over You searched for: Author "Pinder-Schenck M" Remove constraint Author: "Pinder-Schenck M"
16 results on '"Pinder-Schenck M"'

Search Results

1. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology

2. Phase 1B Study of Oral Dual-Pi3K/Mtor Inhibitor Gdc-0980 in Combination with Carboplatin (Carbo)/Paclitaxel (Pac) ± Bevacizumab (Bev) and Cisplatin (Cis)/Pemetrexed (Pem) in Patients (Pts) with Advanced Solid Tumors and Nsclc

3. 1230PD - Phase 1B Study of Oral Dual-Pi3K/Mtor Inhibitor Gdc-0980 in Combination with Carboplatin (Carbo)/Paclitaxel (Pac) ± Bevacizumab (Bev) and Cisplatin (Cis)/Pemetrexed (Pem) in Patients (Pts) with Advanced Solid Tumors and Nsclc

5. Non-small cell lung cancer: Clinical practice guidelines in oncology

6. Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines

7. CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition.

8. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.

9. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.

10. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.

11. Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.

12. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

13. Systemic and targeted therapies for early-stage lung cancer.

14. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

15. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement.

16. Neoadjuvant chemotherapy for non-small cell lung cancer.

Catalog

Books, media, physical & digital resources